Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Recruiting
Phase 2
Phase 3
Interventional Study
Retinopathy of Prematurity
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 1 Month – 12 Months
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Sponsor
- Asociación para Evitar la Ceguera en México · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF ex…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY
Exclusion Criteria:
* PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER
Contacts